Article Text

Download PDFPDF

Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction
  1. Hiroyoshi Takeuchi,
  2. Gary Remington
  1. Schizophrenia Division, Complex Mental Illness Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada
  1. Correspondence to Dr Hiroyoshi Takeuchi, hirotak{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

ABSTRACT FROM: Graff-Guerrero A, Rajji TK, Mulsant BH, et al. Evaluation of antipsychotic dose reduction in late-life schizophrenia: a prospective dopamine D2/3 receptor occupancy study. JAMA Psychiatry 2015;72:927–34.

What is already known on this topic

The use of lower doses of antipsychotics is recommended by experts in the treatment of older patients with schizophrenia, with the literature suggesting that older age is related to greater antipsychotic sensitivity.1 To date, three randomised controlled trials have examined the effects of olanzapine and risperidone dose reduction on clinical outcome in schizophrenia with inconsistent results.2–4 However, this topic has not been addressed specifically in older patients with schizophrenia, nor has the relationship between decreased dopamine D2/3 receptor occupancy and clinical response.

Methods of the study

The study, using [11C]-raclopride positron emission tomography (PET), is an open-label, single-arm, prospective study. A total of 35 outpatients, 50 years or older, with clinically stable schizophrenia and receiving the …

View Full Text


  • Competing interests HT has received fellowship grants from the Canadian Institutes of Health Research (CIHR), Centre for Addiction and Mental Health (CAMH) Foundation, the Japanese Society of Clinical Neuropsychopharmacology and Astellas Foundation for Research on Metabolic Disorders, and manuscript fees from Dainippon Sumitomo Pharma. GR has received research support from Novartis, Medicure and Neurocrine Bioscience, as a co-investigator he has received grant support from Pfizer Inc, consultant fees from Laboratorios Farmacéuticos ROVI, Synchroneuron, Novartis and Roche and speaker's fees from Novartis.